FEDERAL COURT OF AUSTRALIA
New England Biolabs, Inc v F. Hoffmann-La Roche AG [2004] FCA 1651
INTELLECTUAL PROPERTY – patents – appeal from decision of Commissioner of Patents to allow amendments – Patents Act 1990 (Cth) ss 40, 102, 104 – whether as a result of amendments certain claims would not fall within scope of claims of specification before amendment – no impermissible broadening of claims – no requirement in the Patents Act that the best method disclosed in a specification must actually have been performed by the applicant
Patents Act 1990 (Cth), ss 40, 102, 104.
F. Hoffmann-La Roche AG v Commissioner of Patents [2000] FCA 1845 cited
New England Biolabs Inc v Commissioner of Patents (2001) 110 FCR 357 cited
AMP Incorporated v Commissioner of Patents (1974) 3 ALR 283 citedNEW ENGLAND BIOLABS, INC v F. HOFFMANN-LA ROCHE AG
N1305 OF 2003
EMMETT J
15 DECEMBER 2004
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N1305 OF 2003
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
NEW ENGLAND BIOLABS, INC
APPLICANTAND:
F. HOFFMANN-LA ROCHE AG
RESPONDENTJUDGE:
EMMETT J
DATE OF ORDER:
15 DECEMBER 2004
WHERE MADE:
SYDNEY
THE COURT ORDERS THAT:
The appeal be dismissed with costs.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N1305 OF 2003
ON APPEAL FROM THE COMMISSIONER OF PATENTS
BETWEEN:
NEW ENGLAND BIOLABS, INC
APPLICANTAND:
F. HOFFMANN-LA ROCHE AG
RESPONDENTJUDGE:
EMMETT J
DATE:
15 DECEMBER 2004
PLACE:
SYDNEY
REASONS FOR JUDGMENT
This is another stage in the dispute concerning Patent Application No. 632857 (‘the Patent Application’), which relates to a purified thermostable DNA polymerase. This proceeding is an appeal under s 104(7) of the Patents Act 1990 (Cth) (‘the Act’) from a decision of the Commissioner of Patents allowing amendments at the behest of the respondent, F. Hoffmann-La Roche AG (‘Hoffmann’). The amendments were opposed by the applicant, New England Biolabs, Inc (‘NEB’).
PROCEDURAL BACKGROUND
The Patent Application was filed on 8 October 1990. It was advertised as accepted on 14 January 1993 and notice of opposition was filed by NEB on 14 April 1993. On 12 November 1997, a delegate of the Commissioner upheld the opposition in relation to certain claims but rejected the opposition in relation to the balance of the claims. While the Commissioner’s delegate reserved to Hoffmann the right to request amendments, that right was not taken up at that stage. Rather, both parties appealed to this Court under s 60 of the Act in so far as the delegate’s decision was contrary to its interests.
The appeals under s 60 came before me and, on 28 April 2000, in giving a ruling on the admissibility of evidence in the course of the hearing of the appeals, I expressed my views as to the nature of an appeal in opposition proceedings: see F. Hoffmann-La Roche AG v New England…
Keep reading for free
Create a free CaseChat account to read New England Biolabs, Inc v F. Hoffmann-La Roche AG and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2004] FCA 1651
- Decision Date
CaseChat Overview and Summary
The Court considered the statutory framework and the specific language of the claims in the Patent Application. It found that Claim 3, when read in conjunction with Claim 1, was broader than Claim 86. Therefore, the proposed amendments would not result in Claim 86 being broader than Claim 3, which would otherwise contravene sections 102(1) and 102(2)(a) of the Act. The Court concluded that the Commissioner’s delegate had not erred in granting leave for the amendments. The Court further found that NEB’s arguments concerning inequitable conduct did not affect the discretion to grant leave for amendments.
As a result of this reasoning, the Court dismissed the appeal. The Court determined that none of the grounds relied upon by NEB had been substantiated, and therefore, the appeal was dismissed with costs.
ORDERS:
1. The appeal be dismissed with costs.
Orders
Orders of the court
1.
The appeal be dismissed with costs.
Background
Background to the litigation
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: EMMETT J
The court considered whether the Commissioner of Patents has the discretionary power to grant leave to amend the specification at the stage of granting leave. The court noted that the Commissioner's decision to grant leave was not subject to judicial review until after the amendment had been made. The court concluded that the Commissioner did indeed have the authority to grant such leave at that stage, as the power to grant leave to amend is a discretionary one vested in the Commissioner.
The court then turned to the question of whether the proposed amendments to the specification would broaden the claims, which would be precluded by sections 102(1) and 102(2)(a) of the Patents Act 1990 (Cth). The court examined the proposed amendments in light of the existing claims, particularly Claim 3. The court found that Claim 3, as construed, included the content of Claim 86. Therefore, the proposed amendments would not broaden the claims, as they would not introduce new subject matter that was not already covered by Claim 3. Consequently, sections 102(1) and 102(2)(a) of the Patents Act 1990 (Cth) did not preclude the amendments.
In reaching its decision, the court applied the principles of statutory interpretation and the specific provisions of the Patents Act 1990 (Cth) concerning amendments to patent specifications. The court followed established authority on the Commissioner's discretionary powers and the scope of permissible amendments under the Act. The ratio decidendi of this decision is that the Commissioner of Patents has the discretion to grant leave to amend a specification at the stage of granting leave, and such amendments do not necessarily broaden the claims if they are consistent with the scope of existing claims.